Copyright
©The Author(s) 2022.
World J Gastroenterol. Oct 21, 2022; 28(39): 5679-5690
Published online Oct 21, 2022. doi: 10.3748/wjg.v28.i39.5679
Published online Oct 21, 2022. doi: 10.3748/wjg.v28.i39.5679
Table 1 Some clinical trials supporting the usefulness of restriction of advanced glycation end-products intake in human cancers
| Ref. | Year | Condition | Outcome |
| Jiao et al[102] | 2015 | Pancreatic cancer | Increased risk of pancreatic cancer |
| Peterson et al[103] | 2020 | Breast cancer | Increased breast cancer risk in postmenopausal women |
| Omofuma et al[104] | 2020 | Breast cancer | Increased risk of breast cancer |
| Aglago et al[105] | 2021 | Colorectal cancer | Increased risk of CRC |
| Mao et al[106] | 2021 | Colorectal cancer | Increased CRC mortality in non-T2D patients |
| Omofuma et al[107] | 2021 | Breast cancer | Increased breast cancer mortality |
| Mayén et al[32] | 2021 | Hepatobiliary cancers | Increased risk of gallbladder cancer |
- Citation: Rojas A, Lindner C, Schneider I, Gonzàlez I, Morales MA. Receptor of advanced glycation end-products axis and gallbladder cancer: A forgotten connection that we should reconsider. World J Gastroenterol 2022; 28(39): 5679-5690
- URL: https://www.wjgnet.com/1007-9327/full/v28/i39/5679.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i39.5679